» Articles » PMID: 36359834

The Ion Channel Gene KCNAB2 Is Associated with Poor Prognosis and Loss of Immune Infiltration in Lung Adenocarcinoma

Overview
Journal Cells
Publisher MDPI
Date 2022 Nov 11
PMID 36359834
Authors
Affiliations
Soon will be listed here.
Abstract

The malignancy with the greatest global mortality rate is lung cancer. Lung adenocarcinoma (LUAD) is the most common subtype. The evidence demonstrated that voltage-gated potassium channel subunit beta-2 (KCNAB2) significantly participated in the initiation of colorectal cancer and its progression. However, the biological function of KCNAB2 in LUAD and its effect on the tumor immune microenvironment are still unknown. In this study, we found that the expression of KCNAB2 in tissues of patients with LUAD was markedly downregulated, and its downregulation was linked to accelerated cancer growth and poor clinical outcomes. In addition, low KCNAB2 expression was correlated with a deficiency in immune infiltration. The mechanism behind this issue might be that KCNAB2 influenced the immunological process such that the directed migration of immune cells was affected. Furthermore, overexpression of KCNAB2 in cell lines promoted the expression of CCL2, CCL3, CCL4, CCL18, CXCL9, CXCL10, and CXCL12, which are necessary for the recruitment of immune cells. In conclusion, KCNAB2 may play a key function in immune infiltration and can be exploited as a predictive biomarker for evaluating prognosis and a possible immunotherapeutic target.

Citing Articles

Targeting ion channels: innovative approaches to combat cancer drug resistance.

Shi Q, Yang Z, Yang H, Xu L, Xia J, Gu J Theranostics. 2025; 15(2):521-545.

PMID: 39744692 PMC: 11671388. DOI: 10.7150/thno.103384.


Identification and validation of ion channels-related mRNA prognostic signature for glioblastomas.

Huang C, Yu X, Zhou Y, Bao W Medicine (Baltimore). 2024; 103(48):e40736.

PMID: 39612412 PMC: 11608677. DOI: 10.1097/MD.0000000000040736.


Role of pyroptosis-related cytokines in the prediction of lung cancer.

Peng Z, Tan X, Xi Y, Chen Z, Li Y Heliyon. 2024; 10(10):e31399.

PMID: 38813211 PMC: 11133917. DOI: 10.1016/j.heliyon.2024.e31399.


Ion channels in lung cancer: biological and clinical relevance.

Capitani C, Chioccioli Altadonna G, Santillo M, Lastraioli E Front Pharmacol. 2023; 14:1283623.

PMID: 37942486 PMC: 10627838. DOI: 10.3389/fphar.2023.1283623.


KCNAB2 overexpression inhibits human non-small-cell lung cancer cell growth in vitro and in vivo.

Cheng F, Tang Y, Cao Y, Peng S, Zhu X, Sun Y Cell Death Discov. 2023; 9(1):382.

PMID: 37852974 PMC: 10584983. DOI: 10.1038/s41420-023-01679-5.


References
1.
Ko E, Kim Y, Lee D, Choi J, Kim S, Seo Y . Expression of potassium channel genes predicts clinical outcome in lung cancer. Korean J Physiol Pharmacol. 2019; 23(6):529-537. PMC: 6819903. DOI: 10.4196/kjpp.2019.23.6.529. View

2.
Maskalenko N, Zhigarev D, Campbell K . Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov. 2022; 21(8):559-577. PMC: 10019065. DOI: 10.1038/s41573-022-00413-7. View

3.
Comes N, Bielanska J, Vallejo-Gracia A, Serrano-Albarras A, Marruecos L, Gomez D . The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer. Front Physiol. 2013; 4:283. PMC: 3794381. DOI: 10.3389/fphys.2013.00283. View

4.
Propper D, Balkwill F . Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol. 2022; 19(4):237-253. DOI: 10.1038/s41571-021-00588-9. View

5.
Chen S, Su X, Mo Z . KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study. Front Mol Biosci. 2022; 9:812815. PMC: 9205469. DOI: 10.3389/fmolb.2022.812815. View